CVS Health Files 8-K: Director Changes & Executive Compensation

TL;DR

CVS Health board shakeup and exec comp changes filed today.

AI Summary

On November 6, 2024, CVS Health Corporation filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes information on the departure of certain officers, the election of new directors, and updates to compensatory arrangements for key executives. Specific financial details or dollar amounts related to these changes were not immediately available in the provided text.

Why It Matters

This filing signals potential shifts in corporate governance and executive leadership at CVS Health, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate underlying strategic shifts or governance issues that may affect the company's future performance.

Key Players & Entities

• CVS HEALTH Corp (company) — Registrant
• 0000064803 (company) — Central Index Key
• November 6, 2024 (date) — Report Date

FAQ

From the Filing

0001193125-24-251673.txt : 20241106 0001193125-24-251673.hdr.sgml : 20241106 20241106064529 ACCESSION NUMBER: 0001193125-24-251673 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241106 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 241429165 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d781927d8k.htm 8-K 8-K CVS HEALTH Corp false 0000064803 0000064803 2024-11-06 2024-11-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2024       CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter)       Delaware   001-01011   05-0494040 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) One CVS Drive Woonsocket , Rhode Island 02895 (Address of Principal Executive Offices, and Zip Code) (401) 765-1500 Registrant’s Telephone Number, Including Area Code N/A (Former name, former address and former fiscal year, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.01 per share   CVS   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 6, 2024, CVS Health Corporation (the “ Company ”)